Medical Devices Middle East

Middle East Pharmacogenomic Testing Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Middle East Pharmacogenomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Middle East · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $108.8 Mn Placeholder estimate
Estimate 2025 $120.9 Mn 3.8% of the global market
Projected 2034 $314.4 Mn 160% Adds $193.5 Mn over 9 forecast years
CAGR 2025–2034 11.2% Faster than 64% of 173 Medical Devices markets here
Key players 5
  • Middle East is 3.84% of the global market.
  • Among regions, the largest is North America at $1.66 Bn.
  • Fastest growing: Africa at 11.5% a year.
  • Middle East ranks 5th of 6 by size among regions.

Market size projection

Middle East

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$193.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing Market market size by year, Middle East
YearMarket sizeChange that yearSince 2025
2024 (estimate) $108.8 Mn — —
2025 (base) $120.9 Mn +$12.2 Mn —
2026 (forecast) $134.5 Mn +$13.5 Mn +11.2%
2027 (forecast) $149.5 Mn +$15.1 Mn +23.7%
2028 (forecast) $166.3 Mn +$16.7 Mn +37.5%
2029 (forecast) $184.9 Mn +$18.6 Mn +52.9%
2030 (forecast) $205.6 Mn +$20.7 Mn +70%
2031 (forecast) $228.7 Mn +$23.0 Mn +89.1%
2032 (forecast) $254.3 Mn +$25.6 Mn +110.2%
2033 (forecast) $282.7 Mn +$28.5 Mn +133.8%
2034 (forecast) $314.4 Mn +$31.7 Mn +160%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $3.15 Bn
  2. North America $1.66 Bn
  3. US $1.27 Bn
  4. Europe $657.7 Mn
  5. APAC $591.4 Mn
  6. Canada $238.1 Mn
  7. Japan $225.2 Mn
  8. China $224.6 Mn
  9. Latin America $163.4 Mn
  10. Middle East (this report) $120.9 Mn
  11. Germany $98.1 Mn
  12. France $92.2 Mn
  13. Brazil $87.5 Mn
  14. UK $82.5 Mn
  15. Italy $72.6 Mn
  16. India $67.4 Mn
  17. Saudi Arabia $61.2 Mn
  18. Ecuador $59.7 Mn
  19. Africa $55.7 Mn
  20. Spain $52.6 Mn
  21. Mexico $52.1 Mn
  22. Australia $36.2 Mn
  23. New Zealand $33.0 Mn
  24. Russia $31.8 Mn
  25. South Africa $20.7 Mn
  26. UAE $15.7 Mn
  27. Egypt $8.8 Mn
  28. Philippines $7.7 Mn
  29. Malaysia $5.7 Mn
  30. Hong Kong $5.1 Mn
  31. Thailand $3.8 Mn
  32. Singapore $3.7 Mn
  33. Kenya $2.2 Mn

Report snapshot

Middle East Pharmacogenomic Testing Market Analysis at a glance
Market size, 2025$120.9 Mn placeholder estimate
Forecast, 2034$314.4 Mn placeholder estimate
Growth (CAGR), 2025–203411.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc., RPRD Diagnostics (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Middle East Pharmacogenomic Testing Market Analysis Executive Summary

Pharmacogenomic testing checks a person's genes to predict how they will respond to medicines, helping choose the right drug and dose.

Key segments of the pharmacogenomic Testing market include test (Multi-Gene Panels and Single-Gene Tests) and application (Psychiatry, Cardiology and Oncology).

Bar chart: Middle East Pharmacogenomic Testing market size, 2024–2034, placeholder estimates. $108.8 Mn in 2024, $120.9 Mn in 2025 and $314.4 Mn in 2034, 11.2% CAGR.
Middle East Pharmacogenomic Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Middle East Pharmacogenomic Testing Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the pharmacogenomic Testing market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the pharmacogenomic Testing market.

Competitive Landscape for Pharmacogenomic Testing Market in Middle East

The pharmacogenomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing Market in Middle East

Pharmacogenomic Testing in Middle East: rules and payment

In some of the countries we cover here, medical devices are regulated by SFDA (Saudi Arabia)⁠[1] and EDE (UAE)⁠[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)⁠[3] and mandatory health insurance (UAE)⁠[4].

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Emirates Drug Establishment. Checked 14 Nov 2026.

[3] Council of Health Insurance. Checked 14 Nov 2026.

[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Middle East.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing right now, from free public sources.

Latest research 369 papers since 2021 (worldwide)

  1. Mitochondrial mutation m.1555A>G and aminoglycoside-induced hearing loss in neonates: an integrative review. Frontiers in pediatrics, 2026
  2. Genetic determinants of direct oral anticoagulant (DOAC) response: evidence, limitations and barriers to clinical implementation. Expert review of clinical pharmacology, 2026
  3. Advancing Precision Therapeutics in Older Adults: A Scoping Review of Pharmacogenomic Service Models. Clinical pharmacology and therapeutics, 2026
  4. Implementation of Pharmacogenomics in Pediatric-Focused Institutions Within the Pharmacogenomics Global Research Network. Clinical pharmacology and therapeutics, 2026
  5. Genotype-derived interpretive categories of drug response in 908 pharmacogenomic reports from Chinese patients with type 2 diabetes: A retrospective single-centre study. PloS one, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing market in Middle East?
Placeholder estimate: about $120.9 Mn in 2025, rising to about $314.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing market in Middle East growing?
Placeholder estimate: about 11.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Psychiatry, Cardiology, Oncology, Pain Management) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing market?
Key players include Myriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc. and RPRD Diagnostics.
What is driving the Pharmacogenomic Testing market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.
How much research is published on Pharmacogenomic Testing?
PubMed lists 369 papers on Pharmacogenomic Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Pharmacogenomic Testing in Middle East? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions… Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Healthcare In-Vitro Diagnostics: What Comes After COVIDCOVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…
Back to Catalogue
Keep exploring

Related Medical Devices reports in Middle East

See all
Same topic, other categories

Related on genomics and diagnostics and lab testing

See the topic